![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 38, 35574-35585, September 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
,
,
,
,
¶
From the
Department of Genomics and Proteomics,
Beijing Institute of Radiation Medicine, Chinese National Human Genome
Center at Beijing and the § Department of Neuroscience,
Beijing Institute of Basic Medical Sciences, Beijing 100850, China
Received for publication, June 28, 2002
| |
ABSTRACT |
|---|
|
|
|---|
We cloned two novel human transmembrane
semaphorins, (HSA)SEMA6C and (HSA)SEMA6D, that belong to the class VI
subgroup of the semaphorin family. The genes for SEMA6C and SEMA6D are
mapped on chromosome 1q12-21.1 and 15q21.1, respectively. Among the
adult tissues, SEMA6C is expressed only in skeletal muscle,
whereas SEMA6D is expressed abundantly in kidney, brain, and placenta and moderately in the heart and skeletal muscles. During murine development, neither SEMA6C nor SEMA6D was expressed in embryonic day
10.5 (E10.5) embryos, but both were highly expressed in the areas of
the lateral ventricle, the striatum, the wall of the midbrain, the
pons/midbrain junction, and the choroid plexus of E13 embryos.
Were neurons, neither axons nor astrocytes, highly expressed
both semaphorins. Three isoforms of SEMA6C and five isoforms of SEMA6D
derived from alternative splicing were identified, and their expression
was regulated in a tissue- and development-dependent manner. Deletion analysis indicated that a sema domain and a PSI domain
are integrally necessary for correct post-translation modification and
subcellular localization. The extracellular domain of SEMA6C inhibited
axonal extension of nerve growth factor-differentiated PC12
cells and induced the growth cone collapse of chicken dorsal root
ganglion, rat hippocampal neurons, and rat cortical neurons in a
dose-responsive manner. SEMA6D acted like SEMA6C except it had
no significant effect on the growth cones of rat cortical neurons.
Growing axons navigate through the developing embryo with
remarkable accuracy. An axon's response to the guidance cues in its
immediate environment determines the trajectory it will take. Within the past few years, many guidance cues belonging to the semaphorin (1-3), netrin (4), ephrin (5), and slit (6, 7) signaling
molecules families, and to Nogo (8) of the Reticulon family, have all
been shown to attract or repel specific axons in culture and/or to
affect axon guidance in vivo.
All semaphorins contain a semaphorin
(sema)1 domain and a PSI
domain (found in plexins, semaphorins, and integrins) (9) in the
extracellular portion and a class-specific C terminus that may contain
additional sequence motifs. At present, semaphorins have been
categorized into eight subclasses. Class I and class II semaphorins are
found in invertebrates. Classes III to VII are found in vertebrates,
and a final class comprises proteins encoded by viruses. In
vertebrates, class III semaphorins are secreted proteins,
whereas classes IV-VI are transmembrane proteins. Class VI and class
III semaphorins resemble class I and class II semaphorins,
respectively, in their domain arrangements, but both class VI and class
III semaphorins are phylogenetically distinct from class I and class II
semaphorins (1-3).
Recently, many new genes with important biological functions on cell
migration have been detected based on large scale sequencing of human
fetal liver cDNA libraries in our laboratory (10, 11). To identify
potential novel human semaphorin genes, more than 14,000 expressed
sequence tags (ESTs) of human fetal liver cDNA libraries sequenced
in our laboratory (12) have been analyzed to search the non-redundant
GenBankTM data base with the Blast program. Among these
ESTs, an insert clone, FLD6219, with high homology to rat
Sema6C (R-Sema Y) cDNA (13) was selected for
further study.
Here, we report on the molecular cloning, mapping, and functional
analysis of two mammalian semaphorins, (HSA)SEMA6C and (HSA)SEMA6D. Sequencing of the two genes for SEMA6C and SEMA6D indicated that both
are class VI transmembrane semaphorins. Three isoforms of SEMA6C and
five isoforms of SEMA6D, probably generated by alternative splicing,
were identified. Functional studies show that SEMA6C and SEMA6D not
only induce growth cone collapse of dorsal root ganglion (DRG) and
certain cultured rat neurons but also inhibit axonal extension of nerve
growth factor (NGF)-differentiated PC12 cells in a dose-responsive
manner. The expression profiles and genomic organization of the genes
for SEMA6C and SEMA6D are also described.
Identification and cDNA Cloning of Human SEMA6C and
SEMA6D--
Based on a cDNA clone (No. FLD6219)
homologous to rat Sema6C cDNA, we obtained a putative
full-length cDNA of SEMA6C using contig from public data bases, PCR
with primers directly based on the rat Sema6C sequence, and
the 5'-RACE (rapid amplification of cDNA ends) technique (SMARTTM
RACE cDNA Amplification Kit, CLONTECH). Then,
two sets of primers were used to confirm existence of the predicted
cDNA sequence of SEMA6C and to amplify its coding sequence (CDS)
from human brain cDNA. These resulted in pGEM-T vectors with the
entire CDSs of the three alternative splicing variants (SEMA6C.1,
SEMA6C.2, and SEMA6C.3), respectively. To identify any SEMA6C-related
semaphorins in human, we performed a contig search through
sequence databases with SEMA6C.1 cDNA and retrieved two partial
cDNAs (5223 and 1588 bp) susceptible to encoding a SEMA6C-related
semaphorin. Then reverse transcription (RT)-PCRs and 5'-RACE were used
to isolate the full-length cDNA. These resulted in pGEM-T vectors
with the entire CDSs of the five alternative splicing variants
(SEMA6D.1, SEMA6D.2, SEMA6D.3, SEMA6D.4, and SEMA6Ds), respectively.
The primers used above are described in the Supplemental Material.
To distinguish three isoforms of SEMA6C or four long isoforms of
SEMA6D, RT-PCRs were performed using poly(A)+ RNAs of human
tissues (CLONTECH) and total RNAs of rat and mouse tissues. A pair of primers for detecting the 96-bp insertion in SEMA6C were as follows: P7, 5'-AACAGCACGACGGATCATAG-3'; and
P8, 5'-GAGGAGTGGGATGGGGAC-3'. A pair of primers for detecting the 120-bp insertion in SEMA6C were as follows: P9,
5'-GTCTGCGCCTTCTACCTGGA-3'; and P10, 5'-GGCCTGTAAAACATCAAAT-3'. A pair
of primers for detecting the long isoforms of SEMA6D were as follows:
P11, 5'-TAGAGTGACCCCAGGGATGC-3'; and P12, 5'-GACTGGACTTCCCATCGTAC-3'.
The PCR amplification for SEMA6C was performed under the
following conditions: 4 min of initial denaturation at 94 °C
followed by 30 cycles of 94 °C for 45 s, 58 °C for 45 s, and 72 °C for 1 min and ending with a final extension at 72 °C
for 7 min. Amplification used TaKaRa La Taq with GC buffer
(TaKaRa Biotechnology Inc., Dalian, China). The PCR program for
SEMA6D comprised 94 °C for 4 min followed by 30 cycles of
94 °C for 45 s, 55 °C for 45 s, and 72 °C for
45 s. PCR products were separated on agarose gels (1% for
SEMA6C and 2% for SEMA6D), purified from the
gel, and sequenced directly. The principle of computer-based
chromosomal assignment of a new gene was described previously (11).
Sequence Analysis of Human SEMA6C and SEMA6D--
The sequence
alignment and phylogenetic tree among mammalian class semaphorin
proteins were performed using the program CLUSTAL W. Protein
subsequence motifs were identified using the network service SMART
(smart.embl-heidelberg.de). Prosite information of the proteins
was analyzed with the TMpred program, which was used to make a
prediction of membrane-spanning regions and their orientation.
Northern Blot Analysis--
A human multiple tissue Northern
blot (CLONTECH) was hybridized to the specific
probes of SEMA6C, SEMA6D, and actin, respectively. The probes were
generated with the Klenow fragment of DNA polymerase I and
[ Expression Vectors and Immunofluorescence Assay--
To express
semaphorin extracellular domains in soluble forms, the extracellular
domain (including sema domain and PSI domain) of SEMA6C.1 (aa 1-573)
or SEMA6C.3 (aa 1-533) cDNA was subcloned into Myc/His-tagged
expression vector pcDNA3.1-MycHis (Invitrogen) at the
KpnI/EcoRI sites to create the constructs
allowing the expression of C terminally tagged Myc-His fusion proteins,
i.e. SEMA6C.1-mh and SEMA6C.3-mh, respectively. The
constructed plasmids are named pcDNA3.1-SEMA6C.1 and
pcDNA3.1-SEMA6C.3, respectively. Similarly, the extracellular
domain of SEMA6D.1 (aa 1-592) cDNA and the entire CDS of SEMA6Ds
were subcloned in-frame into the pcDNA3.1 vector at the
NotI/XbaI sites and
BamHI/EcoRI sites, leading to
pcDNA3.1-SEMA6D.1 and pcDNA3.1-SEMA6Ds, respectively. pcDNA3.1-SEMA6C.1
For intracellular localization study of the five fusion proteins
mentioned above, COS7 cells transfected with pcDNA3.1-SEMA6C.1, pcDNA3.1-SEMA6C.3, pcDNA3.1-SEMA6C.1- Isolation and Culture of Primary Neurons and in Situ
Hybridization--
The primary neurons were isolated from the spinal
cords of newborn rats (12 h). The spinal cords were dissected out and
cut with scissors into about 1-mm3 blocks. Dulbecco's
modified Eagle's medium with 0.25% trypsin was added and
digested for 30 min at 37 °C, which was terminated by adding the
basic culture medium (Dulbecco's modified Eagle's medium with 10%
fetal bovine serum and 1% N3). After 1 min, the tissue was transferred
into basic medium and rinsed twice. The tissue blocks were then blown
gently with a Pasteur pipette, and then the isolated neurons were
cultured in a basic medium at a density of 0.5 × 105/cm2. After 1 day, arabinosylcytosine
(10 Whole Mount in Situ Hybridization--
Murine embryos (10.5 and
13 days) were dissected free of any extra-embryonic membranes, fixed in
4% paraformaldehyde in DEPC-PBS overnight at 4 °C, washed in
DEPC-PBS, and then stored in 100% methanol at Growth Cone Collapse Assay and Neurite Outgrowth Assay--
COS7
cells (5×105) were transfected with 4 µg of
pcDNA3.1-MycHis vector, pcDNA3.1-SEMA6C.1, or
pcDNA3.1-SEMA6D.1 using LipofectAMINE (Invitrogen) as recommended
by the manufacturer's protocol. 36-48 h after the transfection, the
cells and the conditioned media were collected as described by Luo
et al. (15). Serum-free media containing secreted
SEMA6C.1-mh or SEMA6D.1-mh were concentrated >50-fold using
Centricon Plus-20 filters (Millipore; molecular mass cutoff, 10 kDa) before being used in a growth cone collapse assay. The production
of SEMA6C.1-mh, SEMA6C.3-mh, SEMA6C.1- Identification and Cloning of Human Semaphorin SEMA6C and
SEMA6D--
After sequencing the cDNA libraries of human fetal
liver, a cDNA clone (No. FLD6219, 590 bp) homologous to rat
Sema6C cDNA (13) was picked up to search the dbEST and
the non-redundant GenBankTM data base. Based on a contig
sequence assembly and the experimental confirmation of 5'-RACE and
RT-PCR, we identified (HSA)SEMA6C (Fig.
1), human ortholog of rat
Sema6C and obtained three splicing variants of SEMA6C, here
named SEMA6C.1, SEMA6C.2, and SEMA6C.3, respectively. The longest
isoform (SEMA6C.1, 3845 bp) contained an open reading frame capable of
encoding a 962-amino acid polypeptide with a predicted molecular mass
of 104.3 kDa. The translated sequence, which shows high homology (88%
identity) to rat Sema6C, is composed of a sema domain (aa 64-491)
followed by a PSI domain (aa 518-571) and a transmembrane segments (aa
633-653). It also contains a signal sequence (aa 1-25) at the N
terminus and a proline-rich region (aa 694-874) at the C-terminal
portion. The SEMA6C.2 sequence (3749 bp) encodes a 930-aa polypeptide
and shares the same sequence to the SEMA6C.1 except for a 96-bp
deletion between the extracellular PSI domain and the transmembrane
domain. To our surprise, the SEMA6C.3 sequence (3725 bp) also shares
the same sequence to the SEMA6C.1 except for a 120-bp deletion within
the region coding for the sema domain; and so it encodes only a 922-aa
polypeptide with an incomplete sema domain (Fig.
2A).
To look into whether any SEMA6C-related semaphorins remained to be
identified, we used the human SEMA6C sequence shown above to
search against the non-redundant GenBankTM data base
(BLASTn and BLASTp). Using a similar cloning strategy, we
isolated five full-length cDNA sequences, which represent a single
novel human gene. Amino acid sequence alignment analysis of its
cDNA-coded sequence with those of (HSA)SEMA6C, rat Sema6C, and
mouse Sema6C showed that it contains the typical extracellular domains
of the class VI semaphorin subfamily, such as class VI sema domain and
PSI domain, but differs from all of the known members of this subfamily
(Fig. 1); thus it was called (HSA)SEMA6D. Its four distinct long
isoforms (here named SEMA6D.1, SEMA6D.2, SEMA6D.3, and SEMA6D.4) were
5914, 5875, 5932, and 6100 bp (not including multiple A nucleotides) in
size, encoding 1011, 998, 1017, and 1073 aa, respectively. Sequence
analysis has shown that all of the translated polypeptides are composed
of a signal sequence (aa 1-21) followed by a class VI sema domain (aa
59-477), a PSI domain (aa 508-563), a transmembrane segment, and a
long cytoplasmic region (Fig. 2A).
Phylogenetic analysis shows that the novel transmembrane semaphorin is
closely related to class VI semaphorins, and in mammalian class
VI semaphorins, semaphorin6A and -6B are closer to SEMA6D than
semaphorin6C (Fig. 2B). In the most conserved region (the extracellular domains, i.e. the sema domain and PSI domain),
SEMA6D not only shows considerable similarity to human SEMA6A1
(identities, 60%; positives, 77%), SEMA6C (identities, 52%;
positives, 70%), and SEMA6B (identities, 52%; positives, 68%) but
also moderate similarity (up to 40% amino acid identity)
to many other proteins containing this domain. In addition, the PSI
domain of SEMA6D contains the short cysteine-rich motif,
CX(8)CX(5)CX(3)CX(7)CX(7/8), which is a highly conserved consensus in class VI semaphorins. Taking our findings together, we conclude that this gene is a novel
member of class VI semaphorin. It was named (HSA)SEMA6D according to
the views of the Semaphorin Nomenclature Committee (2).
For the four long isoforms of SEMA6D, an alternative splicing region
was located between the extracellular PSI domain and the transmembrane
domain(Fig. 2C). The shortest mRNA variant (2290 bp,
here designated SEMA6Ds), however, used an early stop codon (because of
a shift in the reading frame) and encoded a truncated polypeptide of
476 aa. The predicted protein is identical to the N-terminal 476-aa
sequence of SEMA6D.1 and contains only a signal sequence followed by a
sema domain but no PSI domain (Fig. 2A).
Genomic Structures and Chromosomal Localization of the Genes for
Human SEMA6C and SEMA6D--
When human SEMA6C and SEMA6D
cDNA sequences were queried against the human genomic data base
using a BLAST search, their corresponding genomic sequences were
fortunately retrieved. The cDNA sequences of human SEMA6C exactly
matched to chromosome 1 clone RP11-68I18 (GenBankTM
accession No. AL592424.1), whereas the cDNA sequences of human SEMA6D exactly matched to chromosome 15 clone RP11-198M11
(GenBankTM accession No. AC018900.8, map 15q21.1) and
chromosome 15 clone CTD-2270N23 (AC044787.6, map 15q21). Then,
alignment between the human SEMA6C or SEMA6D
cDNAs and their genomic sequences revealed that human SEMA6C and
SEMA6D are composed of at least 20 and 19 exons, respectively (Fig.
2C). The sequences of the intron/exon junctions were all
exactly consistent with the typical GT-AG consensus motif of the splice
donor and acceptor sites except for two GC-AG sites (in
introns 1 and 14) in SEMA6C and a GC-AG site (in intron 9)
in SEMA6D. Alignment between the cDNAs and their genomic
sequences also revealed that the human SEMA6C and
SEMA6D genes span about 15 and 58 kb of genomic DNA,
respectively. For human SEMA6C, only SEMA6C.1 contains all
20 of the exons, whereas exon 19 is deleted in SEMA6C.2 and exon 9 in
SEMA6C.3. For human SEMA6D, no cDNA contains all 19 of
the exons. Exons 13b, 17, and 18 are deleted in SEMA6D.1, whereas exons
13b, 16a, 17, and 18 are deleted in SEMA6D.2; exons 13b, 16a, and 18 are deleted in SEMA6D.3; and exons 13b and 16a are deleted in
SEMA6D.4.
Following the principle of computer-based chromosomal mapping described
under "Experimental Procedures," 64 ESTs highly matched to
human SEMA6D cDNA sequence were collected. All of them have been clustered into a Homo sapiens UniGene cluster,
Hs.191098, which has been mapped on chromosome 15q21.1
(www.gdb.org/gdb/) based on the sequence-tagged sites WI-6361, WI-8879,
D15S1223, stSG49296, and D15S1188. Hence, the human SEMA6D
gene should also be mapped on 15q21.1. Similarly, the human
SEMA6C gene is assigned to chromosome 1q12-21.1.1 based on
a UniGene cluster, Hs.54937 (clustered from 37 ESTs), and the marker
stSG28736. The results were confirmed by the genomic sequence search
described above. Recently, a search of the GenBankTM for
sequence similarity with the mouse sequences turned up a high-throughput genomic sequence of a BAC (chromosome 16, clone rp23-11g21, accession No. AC084272.11) containing part of the mouse
Sema6C gene. The sequencing of the BAC was not completed at
the time of this writing.
Expression Distribution of SEMA6C and SEMA6D--
In an attempt to
evaluate the transcript size and transcription profile of the human
SEMA6C, a human multiple tissue Northern blot was hybridized to the
SEMA6C-specific probe. Northern analysis of SEMA6C
expression in 12 human tissues revealed two transcripts of about 4.0 and 6.0 kb (Fig. 3A). The
smaller one (~4.0 kb) is the major transcript, the size of which is
consistent with the cDNAs obtained. The larger transcript (~6.0
kb) is also long enough to cover the three isoforms of
SEMA6C listed above. Among the 12 adult tissues, both of the
transcripts are expressed predominantly in skeletal muscle, moderately
in heart, brain, and kidney, and sparingly in liver and
placenta, but they are hardly detectable in colon, thymus, spleen,
small intestine, lung, and peripheral blood leukocytes. To evaluate the
transcription profile of the short and long isoforms of human SEMA6D,
Northern blot analysis of SEMA6D expression was carried out
using probes derived from the 3' long isoform-specific region and the
5' common region of the SEMA6D cDNAs, respectively. A single band
of ~6.5 kb was detected with the 3'-specific probe in most of the 12 tissues (Fig. 3C), whereas two distinct transcripts (6.5 and
5.0 kb) were identified with the 5' common probe (Fig. 3B).
The larger one, the size of which is consistent with the long isoforms
of SEMA6D, is the major transcript. It is expressed
abundantly in kidney, brain, and placenta, moderately in heart and
skeletal muscle, and sparingly in the lung, colon, and small intestine
but is hardly detectable in liver, spleen, thymus, and peripheral blood
leukocytes. The smaller transcript was expressed faintly in kidney,
skeletal muscle, heart, and placenta and was hardly detectable in the
other eight tissues. The results presented above were confirmed by an
additional dot blot analysis, in which a dot blot containing a total of
68 normal tissues and 8 human cancer lines was hybridized to the same
probes for SEMA6C or SEMA6D, respectively.
Intriguingly, SEMA6C or SEMA6Ds was hardly detectable in the eight human cancer cell lines examined (detailed data
are shown in the Supplemental Material).
In order to get further insight into the role(s) played by these
semaphorins during neural development, we carried out in situ hybridization of murine whole mount embryos. It was
demonstrated that there are no hybridization signals in E10.5 mouse.
However, for E13 mouse embryos, hybridization staining was profound in the brains of all experimental groups. The distribution of positive signals (Fig. 4) was located mainly
around the areas of the lateral ventricle, striatum, wall of midbrain,
pons/midbrain junction, and choroid plexus for 6-DSP (SEMA6Ds probe),
6-CLP (SEMA6C long isoform probe), and 6-DLP (SEMA6D long isoform
probe). Meanwhile, staining on the roof of the neopallial cortex was
also found in 6-DLP and on the spinal cord in 6-CLP. The results
presented above imply important roles for the three genes during the
development of the central nervous system, but there is also
little difference among them.
Moreover, the expression of these semaphorins in neurons was
identified. The primary neurons, isolated from the spinal cords (cortex) of newborn rats, showed a typical appearance of different kinds of neurons, with different sizes and shapes. Under a phase contrast microscope, they became hypertrophic and enlarged beginning at
6 h, and then different numbers of thin processes were seen to
set at each of its termini or around the soma (see Supplemental Material). A few glias were also noted in the dishes. Two days later,
the neuron in the dishes formed a net, and more dense processes also
formed. Fig. 5 shows that almost all of
the neurons in in situ hybridization dishes were
stained by three kinds of special probes such as 6-DSP (SEMA6Ds probe),
6-CLP (SEMA6C long isoform probe), and 6-DLP (SEMA6D long isoform
probe). However, no astrocytes in the dishes were stained. The labeled
neurons, including their perikaryons and processes and even their
termini, were stained with a deep blue color; however, their nuclei
were not stained. We carefully observed the axons but did not find any
labeling. There was no labeling in the control group or in the
perikaryons and processes.
Alternative Splicing of SEMA6C and SEMA6D--
As three SEMA6C
alternatively spliced variants and four SEMA6D long isoforms were
isolated, it was implied that they might have different expression
patterns. To evaluate this possibility for SEMA6C, we first
performed RT-PCR assays using primers designed to give 453- or 357-bp
bands depending on the presence or absence of the 96-bp insertion. As
shown in Fig. 6, mRNA from most
tissues gave both the 453-bp band and the 357-band; however, in muscle the 453-bp band (corresponding to SEMA6C.1 and SEMA6C.3) was far stronger than the 357-band (corresponding to SEMA6C.2), which is
consistent with the result from a previous report on the rat ortholog
(13). When human cerebral cortex and cerebellum were examined by the
same analysis, however, only the 357-bp band was detected, indicating
that SEMA6C.2 is the major transcript in these tissues. To verify the
existence of the human SEMA6C.3 sequence above and assess the
expression profile of the distinct isoforms, we performed RT-PCR using
primers designed to give 495- or 375-bp bands depending on the presence
or absence of the 120-bp insertion. In most of the tissues tested
(i.e. human placenta and cerebellum and human, mouse, and
rat adult skeletal muscle), both the 495-bp band (corresponding to
SEMA6C.1 and SEMA6C.2) and the 375-bp band (corresponding to SEMA6C.3)
were detected, indicating ubiquitous expression of the isoforms. In
muscle, however, the 495-bp band was much stronger than the 375-band.
Thus, the results presented above suggest that SEMA6C.1 is the major
isoform of SEMA6C. In addition, almost none of the 375-bp band
was detected in the adult human cerebral cortex, suggesting that
SEMA6C.3 is expressed exclusively in certain tissues.
As described above (Fig. 2C), human SEMA6D mRNAs include
one short isoform and four long isoforms. The SEMA6D.2 isoform (5875 bp) shares the same sequence to SEMA6D.1 except for a 39-bp deletion between the extracellular PSI domain and the transmembrane domain. The
SEMA6D.3 isoform (5932 bp) shares the same sequence to the SEMA6D.2
sequence except for a 57-bp insertion, whereas the 6100 bp isoform
(SEMA6D.4) shares the same sequence to the SEMA6D.3 sequence except for
a 168-bp insertion nearby the above region. To further verify the
existence of the four long isoforms for human SEMA6D and assess their
relative expression profile, we performed RT-PCR using primers designed
to give 105-, 144-, 162-, or 312-bp bands corresponding to SEMA6D.2,
SEMA6D.1, SEMA6D.3, and SEMA6D.4, respectively. As shown in Fig. 6, the
144 bp band was ubiquitously detected in the adult and fetal human
tissues examined except for the placenta, only the 162-band in almost all the adult tissues, and a significant 312-bp band only in adult muscle and placenta, indicating that SEMA6D.1 is the major transcript. However, the predicted 105-bp band was not detected in any examined tissue so far.
Secretion and Cellular Localization of SEMA6C and
SEMA6D--
Hydrophilic analysis shows that each of the three isoforms
of SEMA6C or the four long isoforms of SEMA6D contains two hydrophobic regions. One is assumed to be a signal sequence and the other a
transmembrane sequence. Thus, all of the proteins are assumed to be
cell surface proteins. On the contrary, since SEMA6Ds contains only a
signal sequence followed by a sema domain (Fig. 2A), it is
assumed to be a secreted protein. Therefore, when their partial cDNAs encoding the extracellular regions (including a signal
sequence, a sema domain, and a PSI domain) or the entire CDS of SEMA6Ds were subcloned into pcDNA3.1-MycHis and expressed transiently in
COS7 cells, it was predicted that the recombinant proteins would be
expressed in soluble form. To confirm this prediction and to facilitate
functional studies of the SEMA6C and SEMA6D genes, the four plasmids
pcDNA3.1-SEMA6C.1, pcDNA3.1-SEMA6C.3, pcDNA3.1-SEMA6Ds, and
pcDNA3.1-SEMA6D.1, described under "Experimental Procedures,"
were expressed transiently in COS7 cells. Expression of the proteins
was confirmed by Western analysis. A unique band is specifically
recognized in each of the cell extracts or the supernatants collected
from pcDNA3.1-SEMA6C.1- or pcDNA3.1-SEMA6D.1-transfected cells
(Fig. 7A). In the cell
lysates, the identified bands are consistent with the predicted sizes
of 62.5 and 67.1 kDa for the unprocessed and the tagged fusion proteins
(including the signal peptide), respectively. In the supernatants,
however, the apparent molecular masses (~75 kDa and 80 kDa,
respectively) were larger than the predicted sizes of 59.7 and 64.7 kDa
(the processed fusion proteins without the signal peptide). This
suggests that the secreted proteins were modified during or after
secretion. Rat Sema6C and other semaphorins have been demonstrated as
glycoproteins (3, 13), and so it is very likely that SEMA6C and SEMA6D
are also glycoproteins. This probability was supported by the
motif searching through Prosite, which indicated that there are three
potential N-glycosylation sites in SEMA6C.1 and nine in
SEMA6D.1.
In the cell extracts collected from pcDNA3.1, SEMA6C.3-, or
pcDNA3.1-SEMA6Ds-transfected cells, the unique bands are also specifically recognized with the predicted sizes of 58.1 and 54.2 kDa
for the unprocessed and the tagged fusion proteins,
respectively (Fig. 7B). In the conditioned medium, however,
no band was specifically recognized, indicating that the fusion
proteins were not secreted. Based on the molecular masses of the fusion
proteins in the cell lysates, the fusion proteins within the host cells
might not be modified with N-linked glycosylation. To
evaluate further the possible roles of different extracellular domains
on subcellular localization of the semaphorin proteins, we
constructed a vector (pcDNA3.1-SEMA6C.1- Growth Cone Collapse Activity of SEMA6C and SEMA6D--
Because
SEMA6C.1 and SEMA6D.1 are demonstrated to be the major isoforms of
SEMA6C and SEMA6D, respectively, soluble versions of SEMA6C.1 and
SEMA6D.1 were engineered for the functional experiments. Medium
conditioned by the cells transfected with SEMA6C.1 or SEMA6D.1 was
concentrated and added to chick E10 DRG explant and cultures, respectively. Growth cone morphology was assessed after a 60-min incubation at 37 °C by fixation and rhodamine-phalloidin staining. The extracellular domain of SEMA6C.1 possesses growth cone-collapsing activity for chick E10 DRG neurons, acutely altering growth cone morphology at concentrations as low as 1.0 mg/ml. It is consistent with
the results of rat Sema6C (13). In addition, the supernatant containing
SEMA6C.1-mh collapsed growth cones of cultured rat hippocampal neurons
and rat cortical neurons in a dose-responsive manner (Fig.
8, A and B). In
comparison, SEMA6D.1-mh was also observed to inhibit axonal extension
of NGF-differentiated PC12 cells and to collapse growth cones of chick
DRG and rat hippocampal neurons but not to collapse growth cones of rat
cortical neurons, even at concentrations as high as 4 mg/ml (Fig.
8C). As a control, medium conditioned by mock-transfected
cells had no apparent collapsing activity. The growth cone collapse and
outgrowth assays suggest that SEMA6C.1 and SEMA6D.1 inhibit axon
outgrowth activity with distinct tissue specificity.
So far more than 25 semaphorin genes have been cloned, and some of
them have been shown to be repulsive signals for growing axons. In the
class VI semaphorins, only mouse Sema6A were reported to have growth
cone collapse activities on chick E8 sympathetic chain ganglia and E7
DRG (19); rat Sema6C has similar activity on chick E8 DRG (13). In this
study, to determine whether SEMA6C and SEMA6D have repulsive activity
on neurons, we performed growth cone collapse assays and a neurite
outgrowth assay using their recombinant secreted proteins instead of
the wild-type transmembrane proteins. Functionally, the extracellular
domain of SEMA6C inhibited axonal extension of NGF-differentiated PC12
cells and induced growth cone collapse of chick DRG, rat hippocampal
neurons, and rat cortical neurons in a dose-dependent
manner. SEMA6D was also observed to inhibit axonal extension of
NGF-differentiated PC12 cells and collapse growth cones of chick DRG
and rat hippocampal neurons but not to collapse growth cones of rat
cortical neurons at the tested concentrations. Under our experimental
conditions, it seems that SEMA6C and SEMA6D have similar potent
repulsive activity on the neurons examined, except on rat cortical
neurons. These data suggest that membrane-bound semaphorins act as
chemo-inhibitory molecules in neuronal development, a role similar to
and likely overlapping with that of the class III semaphorins. However,
the expression of SEMA6C and SEMA6D predominantly in the adult tissues makes them potentially important molecules in nervous system
maintenance and repair. Furthermore, the sensitivities of different
growth cones to distinct semaphorins may be different.
It is worth noting that SEMA6D has an expression profile that overlaps
that of SEMA6A-1, a very close relative of Sema6A. SEMA6A-1 is
expressed highly in the placenta and fetal brain and kidney (20),
whereas SEMA6D is expressed abundantly not only in the placenta and
fetal brain and kidney but also in the adult brain and kidney. This
profile is consistent with a more general role of the proteins in
neurogenesis and organogenesis as well as in regenerative and
degenerative processes; all of these expression areas are characterized
by a highly dynamic rearrangement of cytoskeletal elements (20). It has
been reported that Sema6A has an expression pattern consistent with a
role as a local inhibitor of developing sympathetic axons in
vivo. In addition, another "function unknown" semaphorin,
SEMA6B, was expressed strongly in brain and moderately in heart (21).
Therefore, it is likely that many of these overlapping molecules have
redundant functions acting on any class of axons, but their probable
precise combinations guiding many classes of axons, by process of
elimination, to their target tissues need to be revealed.
Because three isoforms of SEMA6C and five isoforms of SEMA6D have been
isolated, the significance of the alternatively spliced variants
attracted our interest. With Northern blot analysis and RT-PCR, we have
demonstrated their expression to be regulated in a tissue- and
development-dependent manner; SEMA6C.1 and SEMA6D.1 are the
major isoforms of SEMA6C and SEMA6D, respectively. Similarly to rat
Sema6C (13), the alternatively splicing region is located mainly
between the extracellular PSI domain and transmembrane segments for
human SEMA6C and SEMA6D (i.e. SEMA6C.2 and the four long
isoforms of SEMA6D). What is of interest is that SEMA6C.3 contains only an incomplete sema domain, and SEMA6Ds is a "SEMA6D truncate" lacking the PSI domain. The alternative splicing
process related to deletion in the sema domain was described
previously in human SEMA3F (22, 23) and SEMA4F (24). The biological significance of these deletions in the sema domain is inexplicable, because the locations of those deletions correspond to the position of
an important 70 amino acid region within the sema domain, which was
shown to specify the biological activity of the three class III
semaphorins by deletion analysis (25). In addition, similar to SEMA6Ds,
a human "semaphorin 6B truncate" (SEMA6B.1) containing a signal
sequence followed only by a sema domain but lacking the PSI domain has
also been assumed to be a secreted protein by others (21). When the
entire CDS of SEMA6Ds was subcloned into pcDNA3.1-MycHis and
expressed transiently in COS7 cells, however, the
recombinant protein was present only in the cell lysate but was not
detected in the conditioned medium. SEMA6B.1 has not been confirmed to represent a secreted protein by any experiment either. Intriguingly, all of the COS7 cells transfected with the three expression
vectors (pcDNA3.1-SEMA6C.3, pcDNA3.1-SEMA6C.1- Although the cytoplasmic regions of class VI semaphorins are longer
than those of other classes, which are sufficient to have signaling function (20, 24, 27, 28), recent work has begun in
elucidating the nature of the semaphorin receptor. So far, transmembrane semaphorins other than class III have been shown to interact directly with plexins (29-31). Because the plexin family is a large one, it is attractive to suppose that particular plexins will help to determine the specificity of both semaphorin binding and
the biological response. It is hoped that the characterization of the
receptors for SEMA6C and SEMA6D and the further elucidation of their
functions in vivo will facilitate the understanding of the
mechanism of neural development and nerve regeneration after injury and
provide us with possible treatment strategies for certain neurodegenerative diseases.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP using the Prime-a-Gene® labeling system
(Promega). The Northern blot was pre-made with Poly(A)+ RNA
from 12 human tissues. The DNA templates for the probes of SEMA6C (an
XhoI-SacI fragment of 871 bp, nucleotides
2820-3691 of SEMA6C.1), the SEMA6D long isoform-specific probe (a
BamHI fragment of 926 bp, nucleotides 2055-2981 of
SEMA6D.1), the SEMA6D-specific probe (nucleotides 1875-2166 of
SEMA6Ds), and the SEMA6D common probe (a
SacI-PstI fragment of 538 bp, nucleotides
216-853 of SEMA6D.1) were the fragments that were not homologous to
other members of this family. The hybridization procedure followed the manufacturer's protocol. After being washed, the blots were exposed to
x-ray film at
70 °C with an intensifying screen.
PSI was constructed by deleting the PSI
domain from the pcDNA3.1-SEMA6C.1 construct. In brief, two
fragments were amplified from the plasmid pcDNA3.1-SEMA6C.1 using
two sets of primers and were then cut and religated to
pcDNA3.1-MycHis. The following primers were used: P13 (sense),
CGGGGTACCATGCCCCGTGCCCCCCACTTCATGC, and P14 (antisense),
5'-CGGGTCTAGAAAAAGCCACAAAAAGCCTGTG-3'; P15 (sense),
5'-CGGGTCTAGAGCTACTGGGAGTCAGTCTGGC-3', and P16 (antisense), 5'-CGGAATTCAAAGTTGAAACGGCCGCCGTTCGGG-3'. The subcloned inserts were
confirmed by sequencing.
PSI, pcDNA3.1-SEMA6D.1, or pcDNA3.1-SEMA6Ds were fixed in 30% paraformaldehyde,
permeabilized in 0.5% Triton X-100, and stained with anti-Myc
antibody according to standard procedure (14). The nuclei were stained
by Hoechst 33342. All cell samples were viewed under an
epifluorescence microscope.
5 M) was added into the medium, which was
then cultured continuously for another day to kill dividing cells.
Every day thereafter, half of the medium was replaced with appropriate
fresh medium. After removing arabinosylcytosine throughout by two
changes of the N3 culture medium, the neurons were cultured
continuously for another day, and then the neurons were fixed with in
4% paraformaldehyde and 1/1000 DEPC solution (in PBS, pH 7.4) at room
temperature for 30 min. Then, the nonradioactive in situ
hybridization protocols were employed as follows. The neurons were
dipped in 0.5% methanol to extinguish endogenesis peroxidase
for 30 min at room temperature. After being washed, the culture dishes
were incubated in a pepsin solution for 1 min at room temperature to
expose the mRNA section, and then 20 µl of pre-hybridization
solution was added to the dishes for 4 h at 37 °C. Afterward,
20 µl of hybridization solution including differently labeled probes
were added separately into the dishes overnight at 40 °C. After
being washed thoroughly with SSC, the dishes were incubated in antibody
against digoxigenin, conjuncted by biotin for 60 min at
37 °C, and visualized with the BCIP/NBT system for 20-30 min at
room temperature.
20 °C until
required. The embryos were rehydrated in gradient methanol, washed
twice in PTw (1× PBS, 0.1% Tween 20) for 5 min each, treated with 10 µg/ml proteinase K in PTw for 30 min, rinsed once gently in PTw,
re-fixed for 20 min at room temperature, washed twice in PTw for 5 min
at room temperature, and transferred to an 0.5-ml Eppendorf
tube. Then as much liquid as possible was removed while taking care to
avoid damaging the embryos; 0.5 ml hybridization mix (50%
formamide, 5× SSC, 0.5 mg/ml yeast tRNA, 0.5 mg/ml salmon sperm DNA,
5× Denhardt's solution, 0.5% SDS) was added. The mixture was removed
and replaced with fresh hybridization mix, the embryos were
pre-hybridized at 63 °C for 2 h, probe was added to a final
concentration of about 0.5 µg/ml; the mixture was hybridized
overnight at 63 °C and was then rinsed twice with pre-warmed
63 °C hybridization mix, digested with 20 µg/ml RNase A (10 mmol/liter Tris-HCl, 0.5 mol/liter NaCl, 5 mmol/liter EDTA, pH 8.0) for
30 min, twice for 20 min in 2× SSC at 63 °C, twice for 20 min in
0.1× SSC at 63 °C, and once in buffer 1 (0.1 mol/liter maleic acid,
0.15 mol/liter NaCl, pH 7.5). After a 60-min blocking at room
temperature in 5% normal goat serum in buffer 2 (1% blocking reagent
in buffer 1; Roche Molecular Biochemicals), embryos were incubated
overnight at 4 °C in a 1:2000 dilution of anti-digoxigenin Fab
fragment in 5% normal goat serum in buffer 2. They were washed four
times with buffer 1 for 1 h each, washed twice with alkaline
phosphatase buffer (0.1 mmol/liter Tris-HCl, pH 9.5, 0.1 mmol/liter
NaCl, and 50 mmol/liter MgCl2) for 1 h each. For every
ml of alkaline phosphatase buffer, 4.5 µl of NBT and 3.5 µl of BCIP
were added, and the mixture was developed in the dark for 2 to
20 h. When the reaction had proceeded to our satisfaction, it was
imperative to quickly stop the reaction to prevent excess background.
Embryos were washed twice in alkaline phosphatase buffer for 5 min each and then washed at least three times in PTw buffered to pH 5.5 for 1 h each in the dark and fixed in MEMFA (0.1 M MOPS, pH 7.5, 2 mM EGTA, 1 mM MgSO4, 3.7%
formaldehyde) for 1 h. After this time, the embryos could be
cleared in glycerol for visualization.
PSI-mh, SEMA6D.1-mh, or
SEMA6Ds-mh was monitored by Western blot with antibodies against the
c-myc or His6 epitope (Invitrogen). For the
culture of embryonic chick E10 DRG explants, we used the method described by Goshima et al. (16). Primary cultures of
dissociated hippocampal and cerebral cortical neurons were prepared
from the brains of neonatal rats (0-1 day, Wistar) as described by
Enokido et al. (17). Nerve growth factor-differentiated PC12
cells were cultured as described (18). The procedure for growth cone
collapse assays and the method for analysis of total neurite outgrowth were used according to GrandPre et al. (8). For neurite
outgrowth assay, PC12 cells were differentiated in the presence of NGF
(100 ng/ml) for 4-7 days and then trypsinized and re-plated onto
3.5-cm wells precoated with poly-L-lysine. Simultaneously,
the recombinant proteins were added to the culture. After
NGF-differentiated PC12 cells were cultured for 10 to 24 h in the
presence of the indicated proteins, neurite outgrowth was visualized
directly or by staining with rhodamine-phalloidin.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES



View larger version (122K):
[in a new window]
Fig. 1.
Amino acid sequence alignment of
(HSA)SEMA6D.1, (HSA)SEMA6C.1, rat Sema6C, and mouse Sema6C. The
most conserved region is located in their extracellular domains,
i.e. the Sema domain and the PSI domain. The six conserved
cysteines in the cysteine-rich motif,
CX(8)CX(5)CX(3)CX(7)CX(7/8)C,
are shown.

View larger version (13K):
[in a new window]
Fig. 2.
Predicted structure of (HSA)SEMA6C and
(HSA)SEMA6D isoforms and genomic organization of their genes.
A, predicted structure of (HSA)SEMA6C and (HSA)SEMA6D
isoforms are compared with related semaphorin proteins. S,
signal sequence; P, PSI domain; TM, transmembrane
segments; IG, Ig domain; sema, semaphorin domain.
B, phylogenetic tree of mammalian class VI semaphorins is
analyzed only for amino acid sequences of the sema domains and PSI
domains using the CLUSTAL W program. The results were visualized by
TreeView. H, human; M, mouse; R, rat.
C, genomic organization of the
(HSA)SEMA6C and (HSA)SEMA6D
genes. Vertical rectangles, exons; horizontal
lines, introns. The shaded blocks indicate the
alternative splicing regions. For the (HSA)SEMA6C
gene, the SEMA6C.1 isoform contains all 20 of the exons, whereas exons
9 and 19 are deleted in SEMA6C.3 and SEMA6C.2 cDNAs, respectively.
For the (HSA)SEMA6D gene, the SEMA6Ds isoform is
composed of only the first 13 exons. Each of the four long isoforms
contains four to six additional exons at the 3' region and,
interestingly, uses a cryptic acceptor site in exon 13 (described as
exon 13a). In detail, exons 17 and 18 are deleted in SEMA6D.1; exons
16a, 17, and 18 are deleted in SEMA6D.2; exons 16a and 18 are deleted
in SEMA6D.3; and exons 16a is deleted in SEMA6D.4.

View larger version (65K):
[in a new window]
Fig. 3.
Northern blot analysis of
(HSA)SEMA6C and
(HSA)SEMA6D transcription in 12 human
tissues. A human multiple tissue Northern blot (1 µg of
poly(A)+ RNA/lane, CLONTECH) was
hybridized with
-32P-labeled SEMA6C-specific
(A), SEMA6D common (B), or SEMA6D long
isoform-specific (C, upper panel) probe or with a
-actin
cDNA probe (C, lower panel), respectively. Hybridization
with
-actin served as a loading control. Size markers are indicated
on the left.

View larger version (33K):
[in a new window]
Fig. 4.
In situ hybridization of
(HSA)SEMA6C and
(HSA)SEMA6D in
developmental embryos. Murine embryos (10.5 and 13 days) were dissected free of any extra-embryonic membranes. Embryos
were treated with 10 µg/ml proteinase K in PTw for 30 min and
re-fixed in 4% paraformaldehyde + 0.1% glutaraldehyde for 20 min at
room temperature. As much liquid as possible was removed, and the
embryos were prehybridized at 63 °C for 2 h; then probe
was added to a final concentration of about 0.5 µg/ml, and the
embryos were hybridized overnight at 63 °C. A, E10.5
mouse; B, E13 mouse. 6-DSP, SEMA6D short isoform
probe; 6-CLP, SEMA6C long isoform probe; and
6-DLP, SEMA6D long isoform probe.

View larger version (129K):
[in a new window]
Fig. 5.
In situ hybridization of
(HSA)SEMA6C and
(HSA)SEMA6D in neurons.
A and B, photomicrographs show the
neurons, after being cultured for 7 days, forming a neuronet. Dense
processes were also seen between the perikaryons. All of the
neurons in the figure were labeled deeply with 6-DSP (SEMA6Ds probe).
The palest nuclei were noted in the center of the perikaryon;
thick dendrites and deeply stained bead-like processes were
labeled. No axons were labeled. C and D, the
dispersion neurons and neuron cluster, after 4 days of culture, could
be labeled with 6-CLP (SEMA6C long isoform probe). The soma gives rise
to different numbers of deeply stained dendrites. We noted that an
axon-like process seemed to be lightly stained. However, the nuclei
were not stained. E and F, scattered neurons were
labeled by 6-DLP (SEMA6D long isoform probe) after culture for 4 days.
The perikaryons were labeled lightly or deeply, but there was no
labeling in the nuclei.

View larger version (53K):
[in a new window]
Fig. 6.
Distribution of (HSA)SEMA6C and (HSA)SEMA6D
isoforms examined by RT-PCR. Human mRNA
(CLONTECH) or rat and mouse total RNA from various
tissues was used as template for RT-PCR. For (HSA)SEMA6C
(top), a pair of primers gave 495- and 375-bp fragments,
indicating the presence or deletion of a 120-bp insertion; another pair
of primers gave 453- and 357-bp fragments indicating the presence or
deletion of a 96-bp insertion. Panels were normalized against
glyceraldehyde-3-phosphate dehydrogenase. For (HSA)SEMA6D
(bottom), a pair of primers gave 144-, 164-, and 312-bp
fragments representing SEMA6D.1, SEMA6D.3, and SEMA6D.4, respectively.
The predicted 105-bp band (representing SEMA6D.2) was not
detected in any tissue examined so far. Amplified DNA fragments were
fractionated on a 1% (SEMA6C) or 2% (SEMA6D) agarose gel and stained
by ethidium bromide. The fragment sizes are shown on the
left.

View larger version (30K):
[in a new window]
Fig. 7.
Characterization of SEMA6C and SEMA6D
transiently expressed in COS7 cells. The recombinant proteins
(SEMA6C.1-mh, SEMA6C.3-mh, SEMA6C.1-
PSI-mh, SEMA6D.1-mh, and
SEMA6Ds-mh) from both the cell lysates and the conditioned
media (supernatants) were run on a 10% SDS-polyacrylamide gel
under reducing condition and visualized on a Western blot with a
monoclonal antibody against the Myc tag. The predicted bands are
recognized specifically in both the cell lysates (L) and the
supernatants (S) collected from pcDNA3.1-SEMA6C.1- or
pcDNA3.1-SEMA6D.1-transfected cells (A). The 62- and
67-kDa protein bands from the cell lysates containing SEMA6C.1-mh and
SEMA6D.1-mh are consistent with the predicted sizes of the
unprocessed and the tagged proteins, respectively. The
predicted fusion proteins were detected also in the cell lysates from
transfected cells with pcDNA3.1-SEMA6C.3,
pcDNA3.1-SEMA6C.1-
PSI, or pcDNA3.1-SEMA6Ds but not in the
corresponding conditioned media (B). C, cellular
localization of the five fusion proteins displayed by immunostaining of
transfected COS7 cells. COS7 cells were transfected with the five
plasmids listed above. Two days after the transfection, the cells were
fixed with paraformaldehyde and stained with alkaline
phosphatase-labeled anti-Myc antibody. The nuclei were stained
by Hoechst 33342 (data not shown).
PSI) by deleting the PSI
domain of pcDNA3.1-SEMA6C.1. COS7 cells transfected with this vector
did not express the fusion protein in secreted form either, which is
consistent to the results above. To examine further whether the
incomplete extracellular domains have any effect on the intracellular
localization of the proteins, we performed immunostaining of COS7 cells
expressing the five fusion proteins described above using
anti-Myc antibody. As predicted, COS7 cells transfected with
pcDNA3.1-SEMA6C.1 or pcDNA3.1-SEMA6D.1 showed Myc immunoreactivity
on the cell surface and in the cytoplasm (Fig. 7C). In the
cells transfected with pcDNA3.1-SEMA6C.3,
pcDNA3.1-SEMA6C.1-
PSI, or pcDNA3.1-SEMA6Ds, the fusion protein was
detected as punctate green staining distributed throughout the
cytoplasm and even accumulated at the two ends of many cells, which
counted 56.8, 45.2, and 62.5% of the total transfected cells,
respectively. In the other cells, however, the distribution of the
immunoreactive material was similar to that in the cells transfected
with pcDNA3.1-SEMA6C.1 or pcDNA3.1-SEMA6D.1. As seen in Fig.
2A, the expected peptide encoded by pcDNA3.1-SEMA6C.3 contained a truncated sema domain, and the peptide encoded by pcDNA3.1-SEMA6C.1-
PSI or pcDNA3.1-SEMA6Ds contained no PSI
domain at all. Thus, the results support the possibility that a
sema domain and a PSI domain in their integrity are necessary for the appropriate post-translational modification and subcellular
localization of the semaphorin proteins. Those results were further
supported by analysis with the GFP fusion protein localization system
(see Supplemental Materials).

View larger version (13K):
[in a new window]
Fig. 8.
The inhibitory activities of SEMA6C-mh and
SEMA6D-mh for axonal extension. Chick E10 explants and dissociated
rat hippocampal (HN) and cortical neurons (CN)
were cultured and exposed to SEMA6C-mh and SEMA6D-mh collected from the
conditioned media for 60 min before fixation and staining with
rhodamine-phalloidin. The percentage of collapsed growth cones at 2 mg
of total protein/ml (A) and the dose-response curves
comparing the growth cone collapsing activities of SEMA6C-mh
(B) and SEMA6D-mh (C) on chick E10 explants and
dissociated rat HN and CN are shown. Conditioned medium
containing mock MycHis was used as a negative control. All results are the means ± S.E. from four to six
determinations. In A and D, those values that are
significantly different from control are indicated (*,
p < 0.05).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
PSI, or
pcDNA3.1-SEMA6Ds) encoding incomplete extracellular domains could not
secrete the recombinant proteins into the medium. These data plus the
immunofluorescence assay suggest that the integrity of a sema domain or
a PSI domain is necessary for the correct subcellular
localization of the semaphorin proteins. Because the extracellular
region of SEMA4D (CD100) has recently been demonstrated to be released
from the surface of T lymphocytes by regulated proteolysis and thus to
act as a long range guidance cue in the immune system (26), it is
worthwhile to study whether this kind of post-translational
modification is shared by other transmembrane semaphorins.
| |
FOOTNOTES |
|---|
* This work was supported in part by the Chinese National Key Project of Basic Research, the Chinese High-tech Program, and Grants 30070177 and 30070285 from the Chinese National Natural Sciences Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains supplemental data.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF339154 (human SEMA6C.1), AF339152 (human SEMA6C.2), AF339153 (human SEMA6C.3), AF363973 (mouse Sema6C.1), AF363972 (mouse Sema6C.2), AF363971 (rat Sema6C.2), AF389430 (SEMA6D.1), AF389427 (SEMA6D.2), AF389428 (SEMA6D.3), AF389429 (SEMA6D.4), and AF389426 (SEMA6Ds).
¶ To whom correspondence should be addressed: Dept. of Genomics and Proteomics, Beijing Institute of Radiation Medicine, 27 Taiping Rd., Beijing 100850, China. Tel.: 8610-68171208; Fax: 8610-68214653, E-mail: hefc@nic.bmi.ac.cn.
Published, JBC Papers in Press, July 10, 2002, DOI 10.1074/jbc.M206451200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: sema, semaphorpin; PSI, found in plexins, semaphorins, and integrins; EST, expressed sequence tag; RT-PCR, reverse transcription PCR; CDS, coding sequence; RACE, rapid amplification of cDNA ends; DRG, dorsal root ganglion; NGF, nerve growth factor; aa, amino acid(s); contig, contiguous group of overlapping clones; DEPC, diethyl pyrocarbonate; PBS, phosphate-buffered saline; MOPS, 4-morpholinepropanesulfonic acid; E, embryonic day (e.g. E10.5); NBT, nitro blue tetrazolium; BCIP, 5-bromo-4-chloro-3-indolyl phosphate.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Tamagnone, L., and Comoglio, P. M. (2000) Trends Cell Biol. 10, 377-383[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Semaphorin Nomenclature Committee. (1999) Cell 97, 551-552[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Raper, J. A. (2000) Curr. Opin. Neurobiol. 10, 88-94[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Serafini, T., Kennedy, T. E., Galko, M. J., Mirzayan, C., Jessell, T. M., and Tessier-Lavigne, M. (1994) Cell 78, 409-423[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Holder, N., and Klein, R. (1999) Development 126, 2033-2044[Abstract] |
| 6. |
Kramer, S. G.,
Kidd, T.,
Simpson, J. H.,
and Goodman, C. S.
(2001)
Science
292,
737-740 |
| 7. | Wu, W., Wong, K., Chen, J., Jiang, Z., Dupuis, S., Wu, J. Y., and Rao, Y. (1999) Nature 400, 331-336[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | GrandPre, T., Nakamura, F., Vartanian, T., and Strittmatter, S. M. (2000) Nature 403, 439-444[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Bork, P., Doerks, T., Springer, T. A., and Snel, B. (1999) Trends Biochem. Sci. 24, 261-263[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Wang, G.,
Yang, X. M.,
Zhang, Y.,
Wang, Q. M.,
Chen, H. P.,
Wei, H. D.,
Xing, G. C.,
Xie, L.,
Zhang, C. G.,
Fang, D. C., Wu, C. T.,
and He, F. C.
(1999)
J. Biol. Chem.
274,
11469-11472 |
| 11. | Qu, X., Zhang, C., Zhai, Y., Xing, G., Wei, H., Yu, Y., Wu, S., and He, F. (2001) Gene 264, 37-44[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Yu, Y.,
Zhang, C.,
Zhou, G., Wu, S., Qu, X.,
Wei, H.,
Xing, G.,
Zhai, Y.,
Wan, J.,
Ouyang, S., Li, L.,
Zhang, S., Wu, C.,
and He, F.
(2001)
Genome Res.
11,
1392-1403 |
| 13. | Kikuchi, K., Chedotal, A., Hanafusa, H., Ujimasa, Y., de Castro, F., Goodman, C. S., and Kimura, T. (1999) Mol Cell Neurosci. 13, 9-23[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 15. | Luo, Y., Raible, D., and Raper, J. A. (1993) Cell 75, 217-227[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Goshima, Y., Nakamura, F., Strittmatter, P., and Strittmatter, S. M. (1995) Nature 376, 509-514[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Enokido, Y., Akaneya, Y., Niinobe, M., Mikoshiba, K., and Hatanaka, H. (1992) Brain Res. 599, 261-271[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Strittmatter, S. M., Fishman, M. C., and Zhu, X. P. (1994) J. Neurosci. 14, 2327-2338[Abstract] |
| 19. |
Xu, X. M.,
Fisher, D. A.,
Zhou, L.,
White, F. A., Ng, S.,
Snider, W. D.,
and Luo, Y.
(2000)
J. Neurosci.
20,
2638-2648 |
| 20. |
Klostermann, A.,
Lutz, B.,
Gertler, F.,
and Behl, C.
(2000)
J. Biol. Chem.
275,
39647-39653 |
| 21. | Correa, R. G., Sasahara, R. M., Bengtson, M. H., Katayama, M. L., Salim, A. C., Brentani, M. M., Sogayar, M. C., de Souza, S. J., and Simpson, A. J. (2001) Genomics 73, 343-348[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Roche, J., Boldog, F., Robinson, M., Robinson, L., Varella-Garcia, M., Swanton, M., Waggoner, B., Fishel, R., Franklin, W., Gemmill, R., and Drabkin, H. (1996) Oncogene 12, 1289-1297[Medline] [Order article via Infotrieve] |
| 23. |
Sekido, Y.,
Bader, S.,
Latif, F.,
Chen, J. Y.,
Duh, F. M.,
Wei, M. H.,
Albanesi, J. P.,
Lee, C. C.,
Lerman, M. I.,
and Minna, J. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4120-4125 |
| 24. |
Encinas, J. A.,
Kikuchi, K.,
Chedotal, A.,
de Castro, F.,
Goodman, C. S.,
and Kimura, T.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2491-2496 |
| 25. | Koppel, A. M., Feiner, L., Kobayashi, H., and Raper, J. A. (1997) Neuron 19, 531-537[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Delaire, S.,
Billard, C.,
Tordjman, R.,
Chedotal, A.,
Elhabazi, A.,
Bensussan, A.,
and Boumsell, L.
(2001)
J. Immunol.
166,
4348-4354 |
| 27. |
Inagaki, S.,
Ohoka, Y.,
Sugimoto, H.,
Fujioka, S.,
Amazaki, M.,
Kurinami, H.,
Miyazaki, N.,
Tohyama, M.,
and Furuyama, T.
(2001)
J. Biol. Chem.
276,
9174-9181 |
| 28. |
Wang, L. H.,
Kalb, R. G.,
and Strittmatter, S. M.
(1999)
J. Biol. Chem.
274,
14137-14146 |
| 29. | Takahashi, T., Fournier, A., Nakamura, F., Wang, L. H., Murakami, Y., Kalb, R. G., Fujisawa, H., and Strittmatter, S. M. (1999) Cell 99, 59-69[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Tamagnone, L., Artigiani, S., Chen, H., He, Z., Ming, GI., Song, H., Chedotal, A., Winberg, M. L., Goodman, C. S., Poo, M., Tessier-Lavigne, M., and Comoglio, P. M. (1999) Cell 99, 71-80[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Vikis, H. G., Li, W., He, Z.,
and Guan, K. L.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12457-12462 |
This article has been cited by other articles: